Overview
Nawaloka Hospitals provides inpatient, outpatient, diagnostic and specialist healthcare services, including digital-health and international patient offerings. The key change in the latest filing is a divergence between stronger core operations and a much weaker bottom line, making financing and other non-operating charges more important than hospital revenue growth in assessing current earnings quality.
Price performance
At LKR 12.70 on 2 September 2026, NHL had fallen 10.6% over three months against a 4.2% decline in the ASPI. Its one-year return remained 62.8%, well ahead of the index's 3.0% gain.
The share sits 55.3% of the way through its adjusted 52-week range. Recent volatility and 20-day trading volume are both below the company's own one-year and 60-day norms respectively, indicating quieter trading after a volatile longer-term period.
Valuation
NHL trades at 27.72 times earnings, far above the healthcare median of 10.41 times, while its 2.95 times book value is also above the sector median of 1.44 times. The latest audited return on equity was 16.3%, which supports some premium to book value, but does not by itself resolve the much higher earnings multiple.
The stock offers no dividend yield versus a 2.2% sector median. No dividend history or payout record is available, so there is no evidence of a cash distribution offsetting the valuation premium. Sector percentile data is unavailable.
News and sentiment
Direct company coverage is thin: one material article in the past 90 days was positive, with no material company news in the last 30 days. There are no confirmed or pending corporate actions in the supplied data.
Financials
In the June 2026 quarter, gross margin widened from 53.7% to 56.4%, while operating margin improved from 13.7% to 14.5%. Net margin, however, contracted from 24.8% to 2.0%, as charges below operating profit absorbed much of the operating gain.
Revenue and operating profit both grew year-on-year, but net profit fell sharply. Gross margin was among the company's best June-quarter outcomes on the available group-basis record, while operating and net margins were middling against comparable June quarters. Equity increased from the prior year and the share count was unchanged, so the weaker per-share outcome was not caused by a corporate action.
Risks
The principal risk is a stretched balance sheet relative to earnings capacity. Net debt was LKR 6.91 billion at March 2026, with gearing at 111.8% of owners' equity and interest cover only 1.73 times.
Liquidity remains tight, with a current ratio of 0.62. Operating cash flow converted at only 0.44 times operating profit in the latest audited year and free cash flow was negative, meaning reported operating earnings were not fully realised as cash after investment spending.
Outlook
As at 2 September 2026, the next specific event is the filing for the quarter ending 30 September 2026, expected between 12 November 2026 and 2 March 2027. That release will update whether the June gap between operating profit and net profit persisted or narrowed.
As at 2 September 2026, falling government bond yields provide a potentially easier interest-rate backdrop, while inflation and fuel-price pressure remain broader economic risks. The available data cannot determine the company's financing terms, patient volumes or the timing of any earnings recovery before the next filing.